Literature DB >> 16685018

Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis.

Lisa R Young1, Khalid F Almoosa, Stacey Pollock-Barziv, Meg Coutinho, Francis X McCormack, Steven A Sahn.   

Abstract

STUDY
OBJECTIVES: The American College of Chest Physicians Delphi Consensus Statement on management of spontaneous pneumothorax recommended pleurodesis after the first secondary spontaneous pneumothorax to prevent recurrence, and evaluation of patients' perspectives regarding pneumothorax treatment was identified as a future research priority. Patients with lymphangioleiomyomatosis (LAM) are an ideal population for performing these studies, since pneumothorax occurs and recurs more commonly in LAM than in any other chronic pulmonary disorder. STUDY DESIGN AND PARTICIPANTS: A 23-item questionnaire evaluating opinions of pneumothorax treatment was distributed to 615 patients in the LAM Foundation patient database, with a response rate of 52%.
RESULTS: Of respondents, 69% (216 of 314 patients) reported a history of radiographically documented pneumothorax, and 181 patients (84%) reported at least one pleurodesis procedure. Neither a history of pneumothorax nor surgical management of pneumothorax affected reported oxygen use or perception of overall lung function, yet 41% thought that their pneumothorax had contributed to a decline in lung function. Few patients (12%) worried frequently about a pneumothorax developing, but one third made lifestyle modifications due to fear of pneumothorax. Extensive pain associated with chest tube placement and inadequate pain management throughout treatment for pneumothorax were frequent concerns. Only 25% of respondents thought that pleurodesis was appropriate for a first pneumothorax, while 60% favored pleurodesis for a second pneumothorax. Despite the apparent reluctance to undergo pleurodesis, most patients agreed that pleurodesis helps prevent pneumothorax recurrence. One third of patients believed that their physicians did not consider their preferences regarding pneumothorax management.
CONCLUSIONS: LAM patients and physicians may have different views about the significance of pneumothorax, in that most patients appear to favor a conservative initial approach to pneumothorax management. In conjunction with appropriate pain management, a better understanding of patients' perspectives will facilitate cooperative decision making and may ultimately improve clinical outcomes in LAM related to pneumothorax.

Entities:  

Mesh:

Year:  2006        PMID: 16685018     DOI: 10.1378/chest.129.5.1267

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  Unusual causes of pneumothorax.

Authors:  Daniel R Ouellette; Scott Parrish; Robert F Browning; J Francis Turner; Konstantinos Zarogoulidis; Ioanna Kougioumtzi; Georgios Dryllis; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Theodora Tsiouda; Athanasios Madesis; Theodoros Karaiskos; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  Spontaneous pneumothorax in diffuse cystic lung diseases.

Authors:  Joseph Cooley; Yun Chor Gary Lee; Nishant Gupta
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

3.  Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective.

Authors:  Nishant Gupta; Dale Langenderfer; Francis X McCormack; Daniel P Schauer; Mark H Eckman
Journal:  Ann Am Thorac Soc       Date:  2017-01

4.  Spontaneous pneumothorax and air travel in Pulmonary Langerhans cell histiocytosis: A patient survey.

Authors:  Abhishek Singla; Elizabeth J Kopras; Nishant Gupta
Journal:  Respir Investig       Date:  2019-09-26

5.  Sirolimus reduces the risk of pneumothorax recurrence in patients with lymphangioleiomyomatosis: a historical prospective self-controlled study.

Authors:  Chongsheng Cheng; Wenshuai Xu; Yani Wang; Tengyue Zhang; Luning Yang; Wangji Zhou; Danjing Hu; Yanli Yang; Xinlun Tian; Kai-Feng Xu
Journal:  Orphanet J Rare Dis       Date:  2022-07-08       Impact factor: 4.303

6.  Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.

Authors:  Brent W Kinder; A C Sherman; L R Young; J T Hagaman; N Oprescu; S Byrnes; Francis X McCormack
Journal:  Respir Med       Date:  2009-12-04       Impact factor: 3.415

7.  Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.

Authors:  N Oprescu; F X McCormack; S Byrnes; B W Kinder
Journal:  Lung       Date:  2012-09-25       Impact factor: 2.584

8.  Air Travel-Related Spontaneous Pneumothorax in Diffuse Cystic Lung Diseases.

Authors:  Nikolai Wajda; Nishant Gupta
Journal:  Curr Pulmonol Rep       Date:  2018-04-03

9.  Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.

Authors:  Nishant Gupta; Geraldine A Finlay; Robert M Kotloff; Charlie Strange; Kevin C Wilson; Lisa R Young; Angelo M Taveira-DaSilva; Simon R Johnson; Vincent Cottin; Steven A Sahn; Jay H Ryu; Kuniaki Seyama; Yoshikazu Inoue; Gregory P Downey; MeiLan K Han; Thomas V Colby; Kathryn A Wikenheiser-Brokamp; Cristopher A Meyer; Karen Smith; Joel Moss; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

10.  Epidemiology and Healthcare Utilization of Spontaneous Pneumothorax and Diffuse Cystic Lung Diseases in the United States.

Authors:  Ashley Cattran; Karthikeyan Meganathan; Nishant Gupta
Journal:  Ann Am Thorac Soc       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.